Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Scinai Immunotherapeutics ( (SCNI) ) has provided an announcement.
On June 12, 2025, Scinai Immunotherapeutics announced new funding and growth in its CDMO business ahead of the BIO International Convention 2025. The company raised $1.38 million through its Standby Equity Purchase Agreement, enhancing its operational flexibility and financial stability. Scinai’s CDMO business has shown rapid growth, with 2025 revenue expected to reach $2 million, and the company aims to achieve breakeven by the end of 2026. The funding will support the advancement of its nanobody pipeline and expansion of CDMO capacity, positioning Scinai for future collaborations and growth opportunities.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company that focuses on developing inflammation and immunology therapies. It also offers biologics contract development and manufacturing organization (CDMO) services through its Scinai BioServices unit. The company is involved in the development of nanosized VHH antibodies targeting diseases with large unmet medical needs and provides services for early-stage biotech drug development projects.
Average Trading Volume: 355,075
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.18M
For a thorough assessment of SCNI stock, go to TipRanks’ Stock Analysis page.